COVID-19NCT04400812
Attitude and Perception Towards COVID-19 Pandemic
An observational study of COVID-19, run by Zagazig University at 1 site in Egypt.
Trial summary
Assess response and attitude of general population living in Sharkia Governerate, Egypt as regard COVID-19 pandemic through arabic questionnaire. Read more about this study
- Who is it for?
- Ages 16 to 70 years
- Conditions the study is for
- COVID-19
- What is being tested?
- questionnaire
- How many people
- 5,000 participants
- Where
- 1 siteEgypt
- Study dates
- 19 May 2020to Oct 2020
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 16 to 70 years
- All sexes
- Child, Adult, Older adult
Study population: General population within age range (16-70) and both sexes living in Sharkia Governerate, Egypt and accept to participate
Who may be able to join
- General population within age range (16-70) and both sexes living in Sharkia Governerate, Egypt and accept to participate
Who cannot join
- below 16 or above 70 years
- refuse to participate
- duplicate answers
- incomplete answers
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Attitude and Perception of General Population in Sharkia Governerate Towards COVID-19 Pandemic
Assess response and attitude of general population living in Sharkia Governerate, Egypt as regard COVID-19 pandemic through arabic questionnaire.
- Conditions
- COVID-19
- Being tested
- questionnaire
- Medical subject headings
- COVID-19
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
questionnaireOther
Arabic questionnaire focused on knowledge, perception and attitude
What is being measured
The primary outcome is the main question the study is designed to answer.
Knowledge about COVID-19 by questionnaire
Measured: 30 days after enrollment
Perception about COVID-19 by questionnaire
Measured: 30 days after enrollment
Attitude towards COVID-19 by questionnaire
Measured: 30 days after enrollment
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted26 May 2020
- Study start19 May 2020
- Primary completionSep 2020 (estimated)
- Study completionOct 2020 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for COVID-19Studies of the same condition, open and under way.
- More trials run by Zagazig UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Other
- Time perspective
- Cross-sectional
- Enrolment
- 5,000 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Zagazig University
- Sponsor type
- Other government
- Responsible party
- Principal investigator, Waheed Shouman, Zagazig University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04400812
- Sponsor's protocol ID
- ZU#IRB#6138-17-5-2020
- Status last verified
- Aug 2020
- First submitted
- 20 May 2020
- Last updated
- 4 Aug 2020
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 4 Aug 2020. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Attitude and Perception of General Population in Sharkia Governerate Towards COVID-19 Pandemic
- ClinicalTrials.gov ID
- NCT04400812
- Acronym / sponsor ID
- ZU#IRB#6138-17-5-2020
- Conditions
- COVID-19
- Study type
- Observational
- Recruitment status
- Unknown status
- Enrolment
- 5,000 participants (estimated)
- Lead sponsor
- Zagazig UniversityOther government
- Study start
- 19 May 2020 (actual)
- Primary completion
- Sep 2020 (estimated)
- Study completion
- Oct 2020 (estimated)
- First posted
- 26 May 2020 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Assess response and attitude of general population living in Sharkia Governerate, Egypt as regard COVID-19 pandemic through arabic questionnaire.
Study design
- Observational model
- Other
- Time perspective
- Cross-sectional
Who may qualify
- Ages
- 16 to 70 years
- Sex
- All
- Age groups
- Child, Adult, Older adult
- Study population
- General population within age range (16-70) and both sexes living in Sharkia Governerate, Egypt and accept to participate
Key inclusion criteria (1 listed)
- General population within age range (16-70) and both sexes living in Sharkia Governerate, Egypt and accept to participate
Key exclusion criteria (4 listed)
- below 16 or above 70 years
- refuse to participate
- duplicate answers
- incomplete answers
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| questionnaireArabic questionnaire focused on knowledge, perception and attitude | Other | – |
Primary outcome
Knowledge about COVID-19 by questionnaire
Time frame: 30 days after enrollment
Perception about COVID-19 by questionnaire
Time frame: 30 days after enrollment
Attitude towards COVID-19 by questionnaire
Time frame: 30 days after enrollment
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 4 Aug 2020.
Related trials for COVID-19
Not yet recruitingPhase 1
Evaluating AVM0703 for Treatment of COVID-19 or Influenza-mediated ARDS
ARDS, Covid19
Active, not recruitingObservational study
Vaccine Responses to SARS-CoV-2 and Other Emerging Infectious Diseases
COVID-19, Vaccination
RecruitingPhase 4
Comparative Immunogenicity of Respiratory Virus Vaccines (CIRV2) Study
COVID -19, COVID - 19
Not yet recruitingPhase 1
Phase I Open-Label Safety Trial of Pembrolizumab for Neurological Post- Acute Sequelae of SARS-CoV-2 (PD1-PASC I)
Post-Acute COVID-19 Syndrome
RecruitingObservational study
Clinical Outcomes and Pharmacotherapy Effectiveness in the VA Health Care System (COPE-VA)
COVID-19, SARS-CoV-2 Infection, RSV
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of COVID-19, run by Zagazig University at 1 site in Egypt.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 4 Aug 2020. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Egypt. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Knowledge about COVID-19 by questionnaire (time frame: 30 days after enrollment). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 4 Aug 2020.